Pharming « Terug naar discussie overzicht

quote:

't zal maar gebeuren schreef op 11 juni 2018 13:09:

[...]
als die aantallen doorzetten eerder.

quote:

Super trio schreef op 11 juni 2018 13:48:

Karen, hebt jij ooit wel eens wat verdiend met de handel in aandelen. Hahaha

quote:

antop schreef op 11 juni 2018 13:49:

KarenT ......LT!

quote:

Cybertom schreef op 11 juni 2018 14:25:

"GEEN TARGETRISICO, M.A.W. HET WERKT!"

Dit bovenstaande spookt steeds door mijn hoofd sinds afgelopen vrijdag. Dan is het risico op falen toch bijna nihil en zullen alle indicaties de markt kunnen halen. Tenminste, dat maak ik er van. Iemand een andere mening?

quote:

lower schreef op 11 juni 2018 14:26:

Translate Bio teams up with Sanofi in infectious diseases in partnership valued as high as $850M
Jun. 11, 2018 8:20 AM ET|About: Sanofi (SNY)|By: Douglas W. House, SA News Editor

Pending IPO Translate Bio (TBIO) inks a multiyear R&D and licensing agreement with Sanofi's (NYSE:SNY) vaccine unit Sanofi Pasteur aimed at developing mRNA vaccines for up to five undisclosed infectious disease pathogens.

Under the terms of the three-year deal, the companies will jointly conduct R&D to advance the vaccine candidates. Translate Bio will receive $45M upfront, up to $805M in milestones and option exercise fees and tiered royalties on net sales.

Sanofi Pasteur will pay all costs during the research term and will receive exclusive global commercialization rights.

Translate Bio will be responsible for clinical manufacture and will be entitled to additional payments under a separate supply agreement.

seekingalpha.com/news/3362923-transla...

quote:

lower schreef op 11 juni 2018 14:26:

Translate Bio teams up with Sanofi in infectious diseases in partnership valued as high as $850M
Jun. 11, 2018 8:20 AM ET|About: Sanofi (SNY)|By: Douglas W. House, SA News Editor

Pending IPO Translate Bio (TBIO) inks a multiyear R&D and licensing agreement with Sanofi's (NYSE:SNY) vaccine unit Sanofi Pasteur aimed at developing mRNA vaccines for up to five undisclosed infectious disease pathogens.

Under the terms of the three-year deal, the companies will jointly conduct R&D to advance the vaccine candidates. Translate Bio will receive $45M upfront, up to $805M in milestones and option exercise fees and tiered royalties on net sales.

Sanofi Pasteur will pay all costs during the research term and will receive exclusive global commercialization rights.

Translate Bio will be responsible for clinical manufacture and will be entitled to additional payments under a separate supply agreement.

seekingalpha.com/news/3362923-transla...

quote:

Cybertom schreef op 11 juni 2018 14:40:

[...]

Dit zie ik dan bij Pharming niet gebeuren. De Vries gaf aan dat de ontwikkelingskosten relatief zijn en wanneer de kans op succes nagenoeg 100% is, is er geen partner nodig, waardoor alle opbrengsten in de eigen portemonnee verdwijnen. Verder kan Pharming ook nog zelf commercialiseren en distribueren. Een goudmijn!